SYT activators comprise a class of chemical compounds designed to interact with and modulate the activity of Synaptotagmins (SYTs), a group of integral membrane proteins found primarily in neurons and endocrine cells. Synaptotagmins are crucial components of the synaptic vesicle release machinery, where they play a pivotal role in the process of neurotransmitter release at synapses. These proteins contain multiple C2 domains, specialized regions that bind to calcium ions. Calcium binding to these C2 domains triggers a series of events leading to the fusion of synaptic vesicles with the cell membrane and the subsequent release of neurotransmitters into the synaptic cleft, enabling cell-to-cell communication in the nervous system.
The mechanism of action of SYT activators typically involves their interaction with Synaptotagmin proteins, often targeting specific C2 domains. By binding to Synaptotagmins, these activators can influence the calcium-dependent processes that govern neurotransmitter release. This modulation may lead to alterations in the kinetics or efficiency of vesicle fusion, affecting synaptic transmission. As a result, SYT activators are of significant interest to researchers studying the intricacies of synaptic function, as they offer a means to experimentally dissect and manipulate the processes underlying neurotransmitter release, ultimately advancing our understanding of neuronal communication and signaling. Further investigations into the precise molecular interactions and physiological consequences of SYT activators continue to shed light on the complex machinery orchestrating synaptic transmission.
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor that can indirectly affect BAF complex activity by altering chromatin structure and gene expression patterns. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
Suberoylanilide Hydroxamic Acid, another histone deacetylase inhibitor, similarly influences chromatin dynamics, potentially impacting BAF complex function. | ||||||
Panobinostat | 404950-80-7 | sc-208148 | 10 mg | $196.00 | 9 | |
Panobinostat, a broad-spectrum histone deacetylase inhibitor, can indirectly modulate the activity of the BAF complex through changes in chromatin architecture. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $226.00 $846.00 | 1 | |
JQ1, a BET inhibitor, potentially impacts the BAF complex indirectly through its effects on chromatin accessibility and gene transcription. | ||||||
I-BET 151 Hydrochloride | 1300031-49-5 (non HCl Salt) | sc-391115 | 10 mg | $450.00 | 2 | |
I-BET151, another BET inhibitor, may indirectly influence the BAF complex by altering the transcriptional landscape. | ||||||
MS-275 | 209783-80-2 | sc-279455 sc-279455A sc-279455B | 1 mg 5 mg 25 mg | $24.00 $88.00 $208.00 | 24 | |
MS-275, a selective histone deacetylase inhibitor, may have indirect effects on BAF complex activity through epigenetic modulation. | ||||||
RGFP966 | 1357389-11-7 | sc-507300 | 5 mg | $115.00 | ||
RGFP966, a specific HDAC3 inhibitor, can indirectly impact BAF complex function through histone modification changes. | ||||||
PFI 3 | 1819363-80-8 | sc-507340 | 10 mg | $300.00 | ||
PFI-3, a SMARCA bromodomain inhibitor, may indirectly influence the BAF complex through its effect on chromatin accessibility. |